178 related articles for article (PubMed ID: 20137089)
1. Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent.
Altomare DA; Rybak SM; Pei J; Maizel JV; Cheung M; Testa JR; Shogen K
BMC Cancer; 2010 Feb; 10():34. PubMed ID: 20137089
[TBL] [Abstract][Full Text] [Related]
2. Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase.
Vert A; Castro J; Ribó M; Benito A; Vilanova M
Oncotarget; 2017 Feb; 8(7):11692-11707. PubMed ID: 28035074
[TBL] [Abstract][Full Text] [Related]
3. Onconase mediated NFKβ downregulation in malignant pleural mesothelioma.
Goparaju CM; Blasberg JD; Volinia S; Palatini J; Ivanov S; Donington JS; Croce C; Carbone M; Yang H; Pass HI
Oncogene; 2011 Jun; 30(24):2767-77. PubMed ID: 21317924
[TBL] [Abstract][Full Text] [Related]
4. Combination of onconase and dihydroartemisinin synergistically suppresses growth and angiogenesis of non-small-cell lung carcinoma and malignant mesothelioma.
Shen R; Li J; Ye D; Wang Q; Fei J
Acta Biochim Biophys Sin (Shanghai); 2016 Oct; 48(10):894-901. PubMed ID: 27590062
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Jurkat acute T-lymphocytic leukemia cells by onconase (Ranpirnase) is accompanied by an altered nucleocytoplasmic distribution and reduced expression of transcription factor NF-kappaB.
Tsai SY; Ardelt B; Hsieh TC; Darzynkiewicz Z; Shogen K; Wu JM
Int J Oncol; 2004 Dec; 25(6):1745-52. PubMed ID: 15547713
[TBL] [Abstract][Full Text] [Related]
6. Human mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase.
Ramos-Nino ME; Vianale G; Sabo-Attwood T; Mutti L; Porta C; Heintz N; Mossman BT
Mol Cancer Ther; 2005 May; 4(5):835-42. PubMed ID: 15897248
[TBL] [Abstract][Full Text] [Related]
7. Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.
Ardelt W; Shogen K; Darzynkiewicz Z
Curr Pharm Biotechnol; 2008 Jun; 9(3):215-25. PubMed ID: 18673287
[TBL] [Abstract][Full Text] [Related]
8. MiR-379/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma.
Yamamoto K; Seike M; Takeuchi S; Soeno C; Miyanaga A; Noro R; Minegishi Y; Kubota K; Gemma A
Oncol Rep; 2014 Dec; 32(6):2365-72. PubMed ID: 25231602
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling of malignant mesothelioma.
Singhal S; Wiewrodt R; Malden LD; Amin KM; Matzie K; Friedberg J; Kucharczuk JC; Litzky LA; Johnson SW; Kaiser LR; Albelda SM
Clin Cancer Res; 2003 Aug; 9(8):3080-97. PubMed ID: 12912960
[TBL] [Abstract][Full Text] [Related]
10. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
[TBL] [Abstract][Full Text] [Related]
11. [Onconase: a ribonuclease with antitumor activity].
Zwolińska M; Smolewski P
Postepy Hig Med Dosw (Online); 2010 Feb; 64():58-66. PubMed ID: 20173221
[TBL] [Abstract][Full Text] [Related]
12. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
13. Ribonucleases as potential modalities in anticancer therapy.
Ardelt W; Ardelt B; Darzynkiewicz Z
Eur J Pharmacol; 2009 Dec; 625(1-3):181-9. PubMed ID: 19825371
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.
Rybak SM; Pearson JW; Fogler WE; Volker K; Spence SE; Newton DL; Mikulski SM; Ardelt W; Riggs CW; Kung HF; Longo DL
J Natl Cancer Inst; 1996 Jun; 88(11):747-53. PubMed ID: 8637029
[TBL] [Abstract][Full Text] [Related]
15. Effect of Onconase on double-stranded RNA in vitro.
Saxena A; Saxena SK; Shogen K
Anticancer Res; 2009 Apr; 29(4):1067-71. PubMed ID: 19414347
[TBL] [Abstract][Full Text] [Related]
16. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiles in human mesothelioma cell lines in response to interferon-gamma treatment.
Kettunen E; Vivo C; Gattacceca F; Knuutila S; Jaurand MC
Cancer Genet Cytogenet; 2004 Jul; 152(1):42-51. PubMed ID: 15193440
[TBL] [Abstract][Full Text] [Related]
18. Antibody-onconase conjugates: cytotoxicity and intracellular routing.
Rybak SM
Curr Pharm Biotechnol; 2008 Jun; 9(3):226-30. PubMed ID: 18673288
[TBL] [Abstract][Full Text] [Related]
19. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
20. Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis.
Iordanov MS; Ryabinina OP; Wong J; Dinh TH; Newton DL; Rybak SM; Magun BE
Cancer Res; 2000 Apr; 60(7):1983-94. PubMed ID: 10766189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
